Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Hemostemix Inc > Great News!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(36)
•••
Comment by WalterTheDawgon May 17, 2022 3:40pm
113 Views
Post# 34690148

RE:RE:RE:RE:RE:RE:RE:RE:Great News!

RE:RE:RE:RE:RE:RE:RE:RE:Great News!I'd also like to know if we are still interested in trying to license ACP as a treatment in Korea and Japan if results are good or what happened to that? I just remember a lot more enthusiasm about what this phase 2 could do for the company in dec 2020 as opposed to what I'm hearing now. Maybe management is just trying not to overpromise this time which i can appreciate. Let's hope it's a case of underpromise and over deliver when the time comes. Either way I'm here to see trial results and I'm not leaving until we get to see what the numbers say. Should be nothing to stop that now and the chips will fall as they may
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities